Literature DB >> 10640638

Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein.

F Yang1, K Uéda, P Chen, K H Ashe, G M Cole.   

Abstract

Patients with the Lewy body variant (LBV) of Alzheimer's disease (AD) have ubiquitinated intraneuronal and neuritic accumulations of alpha-synuclein and show less neuron loss and tau pathology than other AD patients. Aged Tg2576 transgenic mice overexpressing human betaAPP695. KM670/671NL have limited neuron loss and tau pathology, but frequent ubiquitin- and alpha-synuclein-positive, tau-negative neurites resembling those seen in the LBV of AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640638     DOI: 10.1016/s0006-8993(99)02207-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  22 in total

Review 1.  Alzheimer's disease in man and transgenic mice: females at higher risk.

Authors:  R S Turner
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery.

Authors:  John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

3.  Induction of the unfolded protein response and cell death pathway in Alzheimer's disease, but not in aged Tg2576 mice.

Authors:  Jin Hwan Lee; Sun Mi Won; Jaehong Suh; Sun Joo Son; Gyeong Joon Moon; Ui Jin Park; Byoung Joo Gwag
Journal:  Exp Mol Med       Date:  2010-05-31       Impact factor: 8.718

4.  Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice.

Authors:  Kristel L Emmer; Jason P Covy; Benoit I Giasson
Journal:  Neurosci Lett       Date:  2011-12-13       Impact factor: 3.046

5.  Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice.

Authors:  Jen-Tzer Gau; Michelle L Steinhilb; Tzu-Cheg Kao; Constance J D'Amato; James R Gaut; Kirk A Frey; R Scott Turner
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

6.  Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.

Authors:  Rosa Resende; Sueli C F Marques; Elisabete Ferreiro; Isaura Simões; Catarina R Oliveira; Cláudia M F Pereira
Journal:  Neurochem Res       Date:  2013-02-07       Impact factor: 3.996

Review 7.  Animal models of Alzheimer disease.

Authors:  Frank M LaFerla; Kim N Green
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

Review 8.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

Review 9.  Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.

Authors:  Makoto Hashimoto; Edward Rockenstein; Leslie Crews; Eliezer Masliah
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

10.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.